|Bid||16.69 x 163200|
|Ask||15.11 x 201000|
|Day's range||15.34 - 15.91|
|52-week range||10.45 - 18.61|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||0.24 (2.03%)|
|1y target est||17.06|
What does Crown Resorts Ltd (ASX:CWN) have in common with Commonwealth Bank of Australia (ASX:CBA) and Sirtex Medical Limited (ASX:SRX)? The answer will help you decide if Crown is worth betting on in 2018.
Liver cancer treatments group Sirtex Medical says dosage sales in the first three months of the current financial year have been flat and sales revenue is down because of adverse currency movements, but profit is improving. Chief executive Andrew McClean has told shareholders that the first quarter is showing "some early favourable results" from the company's efforts to improve efficiency and productivity. Sirtex's main product is a medical device called SIR-Spheres Y-90 resin microspheres, to treat liver cancer.
Liver cancer treatments group Sirtex Medical says revenue for the first quarter of 2017/18 has dipped as a result of flat unit sales and adverse currency movements. Sirtex CEO Andrew McClean has told the company's annual general meeting that the first quarter is showing "some early favourable results", dose sales of cancer treatments are flat on the corresponding previous quarter and sales revenue is down about five per cent after currency effects.
WOBURN, Mass.--(BUSINESSWIRE)-- Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX.AX - News), a leading manufacturer of targeted liver cancer therapies, today announced the Combined FOXFIRE Analysis that evaluated SIR-Spheres Y-90 resin microspheres in combination with chemotherapy in patients with mCRC did not improve overall survival compared to chemotherapy alone. The Combined FOXFIRE Analysis is comprised of data from the SIRFLOX study first presented in 2015 and data from two new studies – FOXFIRE and FOXFIRE-Global.
Expert panel reaches uniform consensus that yttrium-90 microspheres is an appropriate option for patients with colorectal liver metastases WOBURN, Mass.--Sirtex Medical Limited (ASX: SRX) today announced ...